CLYM · Climb Bio

The thesis

Climb Bio's budoprutug showed a clear antibody effect in primary membranous nephropathy, and the third-quarter report on 5 November 2026 kept funding guided into the second half of 2028. The December 2026 American Society of Hematology (ASH) presentation in immune thrombocytopenia (ITP) is the next test of whether the drug works beyond one kidney disease.

The company reported on 24 October 2026 that 13 patients in the 200 mg cohort had a mean 70% reduction in anti-PLA2R antibody at Week 12, and 5 of 13 (38%) reached immunologic remission. It reported no proteinuria data. The adjusted close was $11.74 on 10 November 2026, 34.2% below the $17.84 adjusted 52-week high and down 20.3% over three months. The 14-day Relative Strength Index (RSI, a 0–100 momentum gauge) was 55.5, against 44.8 on 28 October 2026, when the close was $10.12.

The story is well known: the headline kidney readout is out, analyst targets were reiterated or raised through 6 November 2026, and the next new information is the ITP poster at ASH on 12 December to 15 December 2026. Systemic lupus erythematosus (SLE) data have moved to 2027, so ITP is the only budoprutug readout guided for the rest of 2026.

Bullish and bearish views on Climb Bio, Inc.

The bull case on Climb Bio, Inc. (CLYM), in brief: cash covers the plan. The bear case: remission rate is modest and open-label.

Bull case

• Cash covers the plan. Climb reported $227.6 million in cash, equivalents and marketable securities at 30 September 2026 and guided funding into the second half of 2028 (Q3 release, 5 November 2026). Quarterly net loss was $14.6 million, or $0.18 per share, against a $0.20 loss consensus estimate.
• Lupus data show dose-dependent activity. In the SLE Phase 1b, 17 participants were enrolled in three single-dose cohorts at the 7 October 2026 cutoff. The 100 mg cohort reached a mean 84% B-cell reduction at Week 12, and the company reported reductions in disease activity (Q3 release, 5 November 2026).
• Antibody reduction matches earlier work. The 24 October 2026 release reports a 70% mean anti-PLA2R reduction at Week 12 at 200 mg, and a 600 mg cohort with 98% mean B-cell suppression at Week 4 versus 74% at 200 mg. Guggenheim wrote on 26 October 2026 that the Phase 3 dose will likely exceed 200 mg.
• Safety is clean so far. The company reported no serious treatment-related adverse events, discontinuations due to adverse events or infusion reactions in the membranous nephropathy trial (Q3 release, 5 November 2026).
• Analysts remain far above the price. Wedbush raised its target to $27 with an Outperform rating on 6 November 2026. Piper Sandler's target is $40 and Guggenheim's is $35 (Investing.com, 26 October 2026 and 27 October 2026).
• A second drug is moving. Dosing has started in the NAVIGATE-2 Phase 2 trial of CLYM116 in IgA nephropathy, with initial data expected in the first half of 2027 and a global Phase 3 start planned for 2027, pending regulatory feedback (Q3 release, 5 November 2026).

Bear case

• Remission rate is modest and open-label. Five of 13 patients reached immunologic remission at Week 12 with no control arm (company release, 24 October 2026). Most of the cohort did not reach remission at 200 mg.
• Proteinuria is still missing. The 24 October 2026 release contained no proteinuria results, and the company says data from all cohorts, including the enrolling 1000 mg cohort, arrive in 2027 (Q3 release, 5 November 2026).
• Spending is rising. Research and development expense was $11.0 million in the third quarter against $9.1 million a year earlier (Q3 release, 5 November 2026). Cash was $239.2 million at 30 June 2026 and $227.6 million at 30 September 2026.
• Placement shares can still be sold. A resale registration filed 29 May 2026 covers up to 11.59M shares from the $9.50 private placement of 28 April 2026. RA Capital-affiliated entities hold a reported 10% stake in Form 4 filings.
• Lupus and ITP evidence is early. The SLE data come from 17 participants in single-dose cohorts, and the ITP poster covers a dose-escalation study with a primary goal of safety and tolerability (ClinicalTrials.gov listing NCT07043946). A small early cohort cannot settle efficacy.

Price setup

The adjusted close was $11.74 on 10 November 2026. That is 34.2% below the $17.84 adjusted 52-week high and above the $10.12 close of 28 October 2026. The shares fell about 18% in the week to 27 October 2026, when Piper Sandler quoted $9.21, so the recent bounce has recovered part of the post-readout drop. The 14-day RSI of 55.5 sits in the middle of its range.

The $9.50 private placement price and the $9.21 quote of 27 October 2026 mark the lower reference points. The shares are 20.3% lower over three months, so the three-month trend is still down. The ASH poster is a dated event that can move the shares in either direction.

Crowding evidence is limited. Sell-side coverage is dense, with targets from $25 to $40 across eleven firms in September to November 2026. The only observable supply overhang is the resale registration covering up to 11.59M shares. No moving-average or short-interest figures are cited here.

Catalysts ahead

• 12 December 2026: ASH 2026 poster: budoprutug Phase 1b in immune thrombocytopenia (meeting runs 12 December to 15 December 2026). First platelet-response data outside kidney disease; shows whether budoprutug's activity extends to a second indication.
• 31 December 2026: End of the year in which the company guided ITP data. A missed ITP disclosure would break the guided timetable.
• 2027 (est.): PrisMN data from all cohorts, including 600 mg and the enrolling 1000 mg cohort, with proteinuria. Decides the Phase 3 dose and whether proteinuria improves alongside antibody levels.
• H1 2027 (est.): Initial NAVIGATE-2 Phase 2 data for CLYM116 in IgA nephropathy. First efficacy read for the second drug, ahead of a planned 2027 Phase 3 start pending regulatory feedback.

What would change the view

A daily close below $9.00, under the $9.50 private placement price and the $9.21 price quoted on 27 October 2026. Proteinuria data that show no response in PrisMN, or a serious safety event at higher doses, would also break the case.

The risks this note tracks, each with what would confirm it:

• Antibody reductions do not translate into proteinuria relief in later PrisMN data. Confirmed by: proteinuria results from the 200 mg or 600 mg cohorts show little change versus baseline.
• The ITP poster shows weak platelet responses at the 500 mg and 1000 mg doses. Confirmed by: ASH data from 12 December 2026 onward show few patients reaching a platelet response.
• Holders of the 2026 private placement shares or insiders keep supplying stock. Confirmed by: more Form 4 sales by directors, or a daily close below $9.00.
• Higher doses introduce new safety findings. Confirmed by: a serious adverse event reported in the 600 mg or 1000 mg PrisMN cohorts.

What it trades with

Climb Bio trades with small and mid-cap clinical-stage biotech, where moves track funding conditions and the Nasdaq Biotechnology complex more than the S&P 500. Single-company events, here the ASH poster and later PrisMN data, drive most of the variance.

Within the company, the budoprutug readouts (membranous nephropathy, ITP, SLE) share one mechanism, an anti-CD19 antibody that depletes B cells, so a strong or weak result in one disease colours the others. CLYM116 in IgA nephropathy is a separate drug with its own partner, Mabworks, and its own timeline.